- Home
- SYNX vs AIM Comparison
SYNX vs AIM Comparison
Compare SYNX & AIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYNX
- AIM
- Stock Information
- Founded
- SYNX 2005
- AIM 1966
- Country
- SYNX Israel
- AIM United States
- Employees
- SYNX N/A
- AIM N/A
- Industry
- SYNX
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SYNX
- AIM Health Care
- Exchange
- SYNX Nasdaq
- AIM Nasdaq
- Market Cap
- SYNX 15.6M
- AIM 15.9M
- IPO Year
- SYNX 2024
- AIM N/A
- Fundamental
- Price
- SYNX $2.61
- AIM $0.22
- Analyst Decision
- SYNX
- AIM Strong Buy
- Analyst Count
- SYNX 0
- AIM 2
- Target Price
- SYNX N/A
- AIM $3.00
- AVG Volume (30 Days)
- SYNX 7.9K
- AIM 295.4K
- Earning Date
- SYNX 11-26-2024
- AIM 11-15-2024
- Dividend Yield
- SYNX N/A
- AIM N/A
- EPS Growth
- SYNX N/A
- AIM N/A
- EPS
- SYNX N/A
- AIM N/A
- Revenue
- SYNX $9,893,000.00
- AIM $190,000.00
- Revenue This Year
- SYNX $52.34
- AIM N/A
- Revenue Next Year
- SYNX N/A
- AIM $1,086.80
- P/E Ratio
- SYNX N/A
- AIM N/A
- Revenue Growth
- SYNX 18.05
- AIM N/A
- 52 Week Low
- SYNX $2.10
- AIM $0.21
- 52 Week High
- SYNX $4.10
- AIM $0.62
- Technical
- Relative Strength Index (RSI)
- SYNX 36.82
- AIM 35.93
- Support Level
- SYNX $2.50
- AIM $0.24
- Resistance Level
- SYNX $2.94
- AIM $0.27
- Average True Range (ATR)
- SYNX 0.25
- AIM 0.02
- MACD
- SYNX -0.01
- AIM -0.00
- Stochastic Oscillator
- SYNX 33.90
- AIM 7.49
About SYNX Silynxcom Ltd.
Silynxcom Ltd is engaged in developing, manufacturing, marketing and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat-proven. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both in training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, market and sell push-to-talk devices, communication controllers, and communication device cables and connectors.
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.